Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For Triple Negative Breast Cancer Participants:
For Ovarian Cancer Participants:
For Gastric Cancer Participants:
For Colorectal Cancer Participants:
For GBM Participants:
For Biliary Tract Cancer Participants:
For Pancreatic Cancer Participants:
Exclusion criteria
For GBM Participants:
Primary purpose
Allocation
Interventional model
Masking
590 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal